R
Ryosuke Goto
Researcher at Janssen Pharmaceutica
Publications - 5
Citations - 242
Ryosuke Goto is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Placebo & Psoriasis Area and Severity Index. The author has an hindex of 4, co-authored 5 publications receiving 136 citations.
Papers
More filters
Journal ArticleDOI
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.
TL;DR: Guselkumab treatment demonstrated efficacy and showed no safety concerns in Japanese patients with GPP and EP through week 52 and consistently showed improvement in responses of secondary end‐points such as Psoriasis Area and Severity Index, Investigator's Global Assessment, Japanese Dermatological Association severity index and improvement in body surface area involvement.
Journal ArticleDOI
Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
TL;DR: In conclusion, guselkumab treatment demonstrated superior efficacy over placebo and was well tolerated in Japanese patients with moderate to severe plaque‐type psoriasis.
Journal ArticleDOI
Efficacy and Safety of Guselkumab in Japanese Patients With Palmoplantar Pustulosis: A Phase 3 Randomized Clinical Trial.
Tadashi Terui,Satomi Kobayashi,Yukari Okubo,Masamoto Murakami,Richuan Zheng,Hitomi Morishima,Ryosuke Goto,Takayuki Kimura +7 more
TL;DR: Efficacy end points improved consistently through week 52, and health-related quality of life also improved significantly, meaning Guselkumab may be an effective and safe treatment option for management of palmoplantar pustulosis.
Journal ArticleDOI
Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
TL;DR: In this article, a double-blind, randomized, double blind (DB), placebo-controlled study was conducted in adult Japanese patients with TRD meeting the Diagnostic and Statistical Manual of Mental Disorders (fifth edition) criteria of major depressive disorder with nonresponse to ≥ 1 but results showed that the difference between the DB induction phase (esketamine and placebo groups was not statistically significant.
Journal ArticleDOI
Efficacy of guselkumab in a subpopulation with pustulotic arthro-osteitis through week 52: an exploratory analysis of a phase 3, randomized, double-blind, placebo-controlled study in Japanese patients with palmoplantar pustulosis.
Toshiyuki Yamamoto,Kunihiko Fukuda,Akimichi Morita,Takayuki Kimura,Hitomi Morishima,Ryosuke Goto,Richuan Zheng,Tadashi Terui +7 more
TL;DR: Previous studies of guselkumab have demonstrated clinical benefits in patients with plaque‐type psoriasis, generalized pustular psOriasis, erythrodermic Psoriasis and palmoplantar pustulosis.